FATE
Fate Therapeutics, Inc.
Price Chart
Latest Quote
$2.18
+0.09 (+4.54%)
Current Price
| Previous Close | $2.09 |
| Open | $2.07 |
| Day High | $2.23 |
| Day Low | $2.01 |
| Volume | 4,586,927 |
Stock Information
| Shares Outstanding | 116.56M |
| Total Debt | $76.78M |
| Cash Equivalents | $174.82M |
| Revenue | $6.32M |
| Net Income | $-129.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $254.66M |
| EPS (TTM) | $-1.10 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $145.57M |
| Sales | $6.32M |
| Income | $-129.91M |
| Book/sh | $1.55 |
| Cash/sh | $1.50 |
| Employees | 161 |
Financial Ratios
| Quick Ratio | 5.75 |
| Current Ratio | 5.85 |
| Debt/Eq | 42.73 |
Returns & Margins
| ROA | -25.29% |
| ROE | -55.50% |
| Operating Margin | -2540.42% |
Ownership
| Insider Ownership | 1.17% |
| Institutional Ownership | 72.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.21 |
| P/S | 40.32 |
| P/B | 1.41 |
Analyst Data
| Recommendation | buy |
| Target Price | $5.41 |
Technical Indicators
| SMA20 | $2.19 |
| SMA50 | $1.88 |
| SMA200 | $1.36 |
| RSI | 31.55 |
| ATR | 0.2096 |
| Shares Float | 101.86M |
| Short Float | 10.40% |
| Short Ratio | 2.29 |
| Volatility | 2.52 |
| Rel Volume | 1.11 |
Performance History
| Week | +6.06% |
| Month | +18.74% |
| Quarter | +98.62% |
| 6 Months | +108.08% |
| YTD | +120.69% |
| Year | +80.56% |
| 3 Years | -59.76% |
| 5 Years | -97.57% |
| 10 Years | +19.39% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $2.18 | 4,586,928 |
| 2026-06-18 | $2.09 | 4,122,800 |
| 2026-06-17 | $1.96 | 1,668,700 |
| 2026-06-16 | $1.90 | 1,862,400 |
| 2026-06-15 | $2.01 | 2,859,100 |
| 2026-06-12 | $2.06 | 4,697,900 |
| 2026-06-11 | $1.97 | 1,743,900 |
| 2026-06-10 | $1.87 | 2,059,500 |
| 2026-06-09 | $1.90 | 1,888,800 |
| 2026-06-08 | $1.91 | 1,368,500 |
| 2026-06-05 | $1.98 | 3,885,700 |
| 2026-06-04 | $2.21 | 3,588,100 |
| 2026-06-03 | $2.22 | 7,555,300 |
| 2026-06-02 | $2.57 | 2,921,600 |
| 2026-06-01 | $2.74 | 7,431,100 |
| 2026-05-29 | $2.84 | 5,191,800 |
| 2026-05-28 | $2.63 | 6,540,200 |
| 2026-05-27 | $2.37 | 7,439,300 |
| 2026-05-26 | $2.15 | 5,573,100 |
| 2026-05-22 | $2.25 | 5,901,700 |
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
đ° Latest News
H.C. Reiterates âBuyâ Rating On Fate Therapeutics (FATE) With $7 PT
Insider Monkey âĸ 2026-06-10T18:22:45Z
Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?
Simply Wall St. âĸ 2026-05-30T14:45:57Z
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-13T13:40:02Z
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T23:05:18Z
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks âĸ 2026-05-06T14:00:05Z
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T13:30:03Z
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference
MarketBeat âĸ 2026-04-16T05:02:42Z
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference
MarketBeat âĸ 2026-03-16T08:02:23Z
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-02-26T18:30:01Z
Fate Therapeutics: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-02-26T14:15:52Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $6,646,000 | $13,631,000 | $63,533,000 | $96,300,000 |
| Operating Revenue | $6,646,000 | $13,631,000 | $63,533,000 | $96,300,000 |
| Expenses | ||||
| Total Expenses | $154,350,000 | $209,170,000 | $254,044,000 | $404,686,000 |
| Other Income Expense | $337,000 | $-8,011,000 | $12,397,000 | $20,823,000 |
| Other Non Operating Income Expenses | $93,000 | $5,907,000 | $9,882,000 | $516,000 |
| Net Non Operating Interest Income Expense | $11,052,000 | $17,288,000 | $17,186,000 | $5,842,000 |
| Operating Expense | $154,350,000 | $209,170,000 | $254,044,000 | $404,686,000 |
| General And Administrative Expense | $46,521,000 | $74,169,000 | $81,448,000 | $84,232,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Net Interest Income | $11,052,000 | $17,288,000 | $17,186,000 | $5,842,000 |
| Interest Income | $11,052,000 | $17,288,000 | $17,186,000 | $5,842,000 |
| Normalized Income | $-136,559,000 | $-172,344,000 | $-163,443,000 | $-302,028,000 |
| Net Income From Continuing And Discontinued Operation | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Total Operating Income As Reported | $-147,704,000 | $-210,276,000 | $-190,511,000 | $-308,386,000 |
| Net Income Common Stockholders | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Net Income | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Net Income Including Noncontrolling Interests | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Net Income Continuous Operations | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Pretax Income | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Special Income Charges | $0 | $-14,737,000 | $0 | - |
| Interest Income Non Operating | $11,052,000 | $17,288,000 | $17,186,000 | $5,842,000 |
| Operating Income | $-147,704,000 | $-195,539,000 | $-190,511,000 | $-308,386,000 |
| Per Share | ||||
| Diluted EPS | $-1.15 | $-1.64 | $-1.64 | $-2.91 |
| Basic EPS | $-1.15 | $-1.64 | $-1.64 | $-2.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-135,047,000 | $-162,659,000 | $-174,744,000 | $-314,935,000 |
| Total Unusual Items | $244,000 | $-13,918,000 | $2,515,000 | $20,307,000 |
| Total Unusual Items Excluding Goodwill | $244,000 | $-13,918,000 | $2,515,000 | $20,307,000 |
| Reconciled Depreciation | $12,901,000 | $18,962,000 | $18,282,000 | $13,758,000 |
| EBITDA (Bullshit earnings) | $-134,803,000 | $-176,577,000 | $-172,229,000 | $-294,628,000 |
| EBIT | $-147,704,000 | $-195,539,000 | $-190,511,000 | $-308,386,000 |
| Diluted Average Shares | $118,789,974 | $113,685,177 | $98,411,162 | $96,826,058 |
| Basic Average Shares | $118,789,974 | $113,685,177 | $98,411,162 | $96,826,058 |
| Diluted NI Availto Com Stockholders | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Impairment Of Capital Assets | $0 | $14,737,000 | $0 | - |
| Gain On Sale Of Security | $244,000 | $819,000 | $2,515,000 | $20,307,000 |
| Research And Development | $107,829,000 | $135,001,000 | $172,596,000 | $320,454,000 |
| Selling General And Administration | $46,521,000 | $74,169,000 | $81,448,000 | $84,232,000 |
| Other Gand A | $46,521,000 | $74,169,000 | $81,448,000 | $84,232,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $207,184,000 | $318,726,000 | $368,417,000 | $483,939,000 |
| Total Assets | $318,937,000 | $440,694,000 | $506,217,000 | $705,561,000 |
| Total Non Current Assets | $110,233,000 | $148,785,000 | $174,677,000 | $203,487,000 |
| Other Non Current Assets | $10,227,000 | $10,236,000 | $15,186,000 | $15,260,000 |
| Investmentin Financial Assets | $1,472,000 | $27,657,000 | $980,000 | $4,942,000 |
| Current Assets | $208,704,000 | $291,909,000 | $331,540,000 | $502,074,000 |
| Other Current Assets | $4,131,000 | $9,302,000 | $14,539,000 | $27,367,000 |
| Receivables | $916,000 | $3,539,000 | $1,826,000 | $38,480,000 |
| Accounts Receivable | $916,000 | $3,539,000 | $1,826,000 | $38,480,000 |
| Cash Cash Equivalents And Short Term Investments | $203,657,000 | $279,068,000 | $315,175,000 | $436,227,000 |
| Cash And Cash Equivalents | $46,628,000 | $36,056,000 | $41,870,000 | $61,333,000 |
| Non Current Accounts Receivable | - | - | - | $7,196,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $77,849,000 | $85,265,000 | $103,536,000 | $109,338,000 |
| Long Term Debt And Capital Lease Obligation | $73,287,000 | $77,849,000 | $97,360,000 | $103,710,000 |
| Current Debt And Capital Lease Obligation | $4,562,000 | $7,416,000 | $6,176,000 | $5,628,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $111,753,000 | $121,968,000 | $137,800,000 | $221,622,000 |
| Total Non Current Liabilities Net Minority Interest | $75,682,000 | $83,446,000 | $98,706,000 | $107,571,000 |
| Other Non Current Liabilities | $2,112,000 | $5,070,000 | - | - |
| Derivative Product Liabilities | $283,000 | $527,000 | $1,346,000 | $3,861,000 |
| Current Liabilities | $36,071,000 | $38,522,000 | $39,094,000 | $114,051,000 |
| Other Current Liabilities | $8,448,000 | - | - | $4,000,000 |
| Current Deferred Liabilities | $381,000 | $393,000 | $685,000 | $42,226,000 |
| Payables And Accrued Expenses | $22,680,000 | $30,713,000 | $32,233,000 | $62,197,000 |
| Payables | $2,656,000 | $9,365,000 | $4,719,000 | $8,265,000 |
| Accounts Payable | $2,656,000 | $9,365,000 | $4,719,000 | $8,265,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $207,181,000 | $318,723,000 | $368,414,000 | $483,936,000 |
| Preferred Stock Equity | $3,000 | $3,000 | $3,000 | $3,000 |
| Total Equity Gross Minority Interest | $207,184,000 | $318,726,000 | $368,417,000 | $483,939,000 |
| Stockholders Equity | $207,184,000 | $318,726,000 | $368,417,000 | $483,939,000 |
| Gains Losses Not Affecting Retained Earnings | $116,000 | $268,000 | $15,000 | $-1,854,000 |
| Other Equity Adjustments | $116,000 | $268,000 | $15,000 | $-1,854,000 |
| Retained Earnings | $-1,534,309,000 | $-1,397,994,000 | $-1,211,732,000 | $-1,050,804,000 |
| Other | ||||
| Ordinary Shares Number | $115,359,735 | $113,928,279 | $98,627,076 | $97,294,917 |
| Share Issued | $115,359,735 | $113,928,279 | $98,627,076 | $97,294,917 |
| Tangible Book Value | $207,181,000 | $318,723,000 | $368,414,000 | $483,936,000 |
| Invested Capital | $207,181,000 | $318,723,000 | $368,414,000 | $483,936,000 |
| Working Capital | $172,633,000 | $253,387,000 | $292,446,000 | $388,023,000 |
| Capital Lease Obligations | $77,849,000 | $85,265,000 | $103,536,000 | $109,338,000 |
| Total Capitalization | $207,184,000 | $318,726,000 | $368,417,000 | $483,939,000 |
| Additional Paid In Capital | $1,741,259,000 | $1,716,335,000 | $1,580,032,000 | $1,536,497,000 |
| Capital Stock | $118,000 | $117,000 | $102,000 | $100,000 |
| Common Stock | $115,000 | $114,000 | $99,000 | $97,000 |
| Preferred Stock | $3,000 | $3,000 | $3,000 | $3,000 |
| Long Term Capital Lease Obligation | $73,287,000 | $77,849,000 | $97,360,000 | $103,710,000 |
| Current Deferred Revenue | $381,000 | $393,000 | $685,000 | $42,226,000 |
| Current Capital Lease Obligation | $4,562,000 | $7,416,000 | $6,176,000 | $5,628,000 |
| Current Accrued Expenses | $20,024,000 | $21,348,000 | $27,514,000 | $53,932,000 |
| Investments And Advances | $1,472,000 | $27,657,000 | $980,000 | $4,942,000 |
| Available For Sale Securities | $1,472,000 | $27,657,000 | $980,000 | $4,942,000 |
| Net PPE | $98,534,000 | $110,892,000 | $158,511,000 | $176,089,000 |
| Accumulated Depreciation | $-36,223,000 | $-35,136,000 | $-47,626,000 | $-30,384,000 |
| Gross PPE | $134,757,000 | $146,028,000 | $206,137,000 | $206,473,000 |
| Other Properties | $27,712,000 | $35,895,000 | $78,853,000 | $77,354,000 |
| Machinery Furniture Equipment | $3,081,000 | $4,140,000 | $6,571,000 | $6,268,000 |
| Buildings And Improvements | $103,964,000 | $105,993,000 | $120,713,000 | $122,851,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $157,029,000 | $243,012,000 | $273,305,000 | $374,894,000 |
| Leases | - | $59,485,000 | $59,038,000 | $56,782,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
| Construction In Progress | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-112,037,000 | $-123,604,000 | $-138,416,000 | $-283,774,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-106,084,000 | $-122,874,000 | $-132,263,000 | $-248,208,000 |
| Cash Flow From Continuing Operating Activities | $-106,084,000 | $-122,874,000 | $-132,263,000 | $-248,208,000 |
| Operating Gains Losses | $9,000 | $942,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-5,953,000 | $-730,000 | $-6,153,000 | $-35,566,000 |
| Investing Cash Flow | $111,166,000 | $12,218,000 | $112,665,000 | $166,751,000 |
| Cash Flow From Continuing Investing Activities | $111,166,000 | $12,218,000 | $112,665,000 | $166,751,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $74,531,000 | $0 | $0 |
| Financing Cash Flow | $5,490,000 | $99,892,000 | $85,000 | $9,207,000 |
| Cash Flow From Continuing Financing Activities | $5,490,000 | $99,892,000 | $85,000 | $9,207,000 |
| Net Other Financing Charges | $5,490,000 | $5,070,000 | - | - |
| Net Common Stock Issuance | $0 | $74,531,000 | $0 | $0 |
| Common Stock Issuance | $0 | $74,531,000 | $0 | $0 |
| Other | ||||
| End Cash Position | $56,855,000 | $46,283,000 | $57,047,000 | $76,560,000 |
| Beginning Cash Position | $46,283,000 | $57,047,000 | $76,560,000 | $148,810,000 |
| Changes In Cash | $10,572,000 | $-10,764,000 | $-19,513,000 | $-72,250,000 |
| Proceeds From Stock Option Exercised | $0 | $20,291,000 | $85,000 | $9,207,000 |
| Net Investment Purchase And Sale | $116,757,000 | $12,948,000 | $118,818,000 | $202,317,000 |
| Sale Of Investment | $311,900,000 | $330,698,000 | $477,628,000 | $607,113,000 |
| Purchase Of Investment | $-195,143,000 | $-317,750,000 | $-358,810,000 | $-404,796,000 |
| Net PPE Purchase And Sale | $-5,591,000 | $-730,000 | $-6,153,000 | $-35,566,000 |
| Sale Of PPE | $362,000 | $0 | - | - |
| Purchase Of PPE | $-5,953,000 | $-730,000 | $-6,153,000 | $-35,566,000 |
| Change In Working Capital | $-3,741,000 | $-1,958,000 | $19,182,000 | $-34,710,000 |
| Change In Other Working Capital | $-2,517,000 | $-4,421,000 | $-1,408,000 | $-828,000 |
| Change In Payables And Accrued Expense | $-9,027,000 | $-1,661,000 | $-28,940,000 | $14,252,000 |
| Change In Prepaid Assets | $5,179,000 | $5,237,000 | $12,876,000 | $-18,330,000 |
| Change In Receivables | $2,624,000 | $-1,113,000 | $36,654,000 | $-29,804,000 |
| Changes In Account Receivables | $2,624,000 | $-1,113,000 | $36,654,000 | $-29,804,000 |
| Other Non Cash Items | $-256,000 | $-1,711,000 | $-40,860,000 | $-24,012,000 |
| Stock Based Compensation | $24,924,000 | $41,496,000 | $43,459,000 | $78,733,000 |
| Asset Impairment Charge | $0 | $14,737,000 | $0 | - |
| Amortization Of Securities | $-3,606,000 | $-9,080,000 | $-11,398,000 | $-256,000 |
| Depreciation Amortization Depletion | $12,901,000 | $18,962,000 | $18,282,000 | $13,758,000 |
| Depreciation And Amortization | $12,901,000 | $18,962,000 | $18,282,000 | $13,758,000 |
| Gain Loss On Sale Of PPE | $9,000 | $942,000 | $0 | - |
| Net Income From Continuing Operations | $-136,315,000 | $-186,262,000 | $-160,928,000 | $-281,721,000 |
| Repayment Of Debt | - | - | - | - |
| Interest Paid Supplemental Data | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
Fetched: 2026-06-18